Business
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic
About this update from Praxis Precision Medicines, Inc.
[{"type":"text","content":"BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies. AES Annual Meeting, being held December 1-5, 2023Behind the Seizure (BTS) Scientific Exhibit, being held on December 3, 2023Partners Against Mortality in Epilepsy (PAME) Conference, being held on November 30, 2023SYNGAP1 Conference, being held on November 30, 2023The Cute Syndrome Foundation (TCSF) SCN8A Clinician, Researcher, and Family Gathering, being held on December 1, 2023 “It’s an incredibly exciting time for Praxis and our epilepsy portfolio, as we share updates from first-in-patient and Phase 2 studies for elsunersen (PRAX-222), PRAX-562 and PRAX-628,” said Marcio Souza, president and chief executive officer of Praxis. “We look forward to presenting data spanning our Solidus and Cerebrum platforms at AES and related meetings in Florida, with presentations also set to highlight novel approaches to define efficient preclinical models and sensitive biomarkers for accelerating drug development for the patient populations we are seeking to serve. Our epilepsy programs have the potential to significantly impact the lives of patients and their families, and we are grateful for the opportunity to discuss these programs with the epilepsy community at multiple important meetings this week.” Praxis at AES 2023 | Orange County Convention Center Meet us at booth #421 to learn about the largest pipeline of precision epilepsy programs Head to one of our presentations listed below or visit us at the BTS Scientific Exhibit on December 3, 08:00 a.m. - 11:00 a.m. ET EMBRAVE: A Clinical Trial of PRAX-222, a Novel Antisense Oligonucleotide, in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy Session Date/Time: Monday, December 4, 12:00 p.m. -...